India has been in the news recently for being one of the countries where most deaths were recorded due to the CCP (Chinese Communist Party) Virus. However, mass distribution of ivermectin has recently begun in the capital city of Delhi, and the results are encouraging, according to Life Site News.

Cases in Delhi, where ivermectin distribution began on April 20, dropped from 28,395 to just 2,260 on May 22. This represents a staggering 92% drop. Similarly, cases in Uttar Pradesh have fallen from 37,944 on April 24 to 5,964 on May 22, a decrease of 84%, reports The Desert Review portal.

Delhi and Uttar Pradesh followed the Indian Institute of Medical Sciences (AIIMS) guidelines issued on April 20, 2021, which called for a dose of 0.2 mg per kilogram of ivermectin per body weight for three days. This equates to 15 mg per day for a 68-kilogram person or 18 mg per day for a 90-kilogram person.

Three other Indian states that adopted ivermectin also drastically reduced the number of cases. Goa dropped cases from 4,195 to 1,647; Uttarakhand dropped from 9,624 to 2,903 and Karnataka from 50,112 to 31,183. Goa adopted a massive prevention policy by dosing ivermectin for the entire adult population over 18 years of age. Prophylaxis consisted of a dose of 12 mg per day for five days.

India would not be the only case. The drop in cases and hospitalizations was also reflected in Mexico City, since the distribution of ivermectin began.

The Government of Mexico City reported on May 14 that according to a study in which it analyzed the use of ivermectin in people infected with the CCP Virus, a reduction of between 52 and 76% in the probability of being hospitalized was identified.

The Head of Government of Mexico City, Claudia Sheinbaum, explained at a press conference that in January of this year a medical group from the Mexican Social Security Institute (IMSS) and the Ministry of Health of the capital met with national and international medical specialists, who administered ivermectin and acetylsalicylic acid.

After detecting that there were practically no side effects, the authorities decided to include these drugs in the first aid kit that the capital’s government provided to the infected patients.
Meanwhile, the head of the Digital Public Innovation Agency of the capital, José Merino, explained that through more than 220,000 observations in people, a reduction in the probability of being hospitalized of between 52 and 76 percent was detected for people who received the kit with the medicines, which among others, included ivermectin.

However, in the U.S. and most countries, government agencies and physicians remain skeptical about using this inexpensive and affordable drug. Even the WHO has refused to recommend it.

Remember that the emergency use authorization under which experimental mRNA vaccines have been approved for mass use would not be granted if there were an accepted effective alternative therapy.

What is the background of ivermectin?

Ivermectin was first discovered in the 1960s by Satoshi Omura, a microbiologist at the Kitasato Institute in Tokyo, and William Campbell, an American biologist and parasitologist who, at the time, was working at Merck Research Labs in New Jersey.

As part of the research agreement between the institute and Merck, Omura isolated microorganisms from soil samples collected in Japan and conducted a preliminary evaluation of their bioactivities in hopes of discovering a new antiparasitic.

Promising samples were then sent to Campbell’s laboratory in the U.S. for further testing.

Among those Campbell received from Omura was a single soil sample containing a potent unknown compound later named avermectin.

To improve avermectin’s safety and biological activity, scientists chemically modified the compound to produce the popular antiparasitic known today as ivermectin.

First introduced as a commercial product for use in animals in 1981, ivermectin proved useful against a wide range of parasites, including lungworms, mites, lice, intestinal worms, and ticks.

Subsequently, Australian researchers found that ivermectin exerts potent anti-viral effects against two viruses that cause life-threatening human diseases, human immunodeficiency virus-1 (HIV-1) and dengue virus (DENV).

Ivermectin has also been found to limit infection by other viral pathogens, such as the Venezuelan equine encephalitis virus and influenza virus.

Because of these reports, other researchers committed to the real welfare of people decided to test the activity of ivermectin against the CCP Virus. If more and more people dare to take this step, a substantial change in the health care industry may soon be achieved.